tbuckley/cabot-search huggingface dataset:
Regulatory roles of three miRNAs on allergen mRNA expression in <i>Tyrophagus putrescentiae</i>
Authors: Ying Zhou, Qingqing Li, Ruilin Pan, Qiong Wang, Xuming Zhu, Cunyin Yuan, Fangfang Cai, Ya‐dong Gao, Yubao Cui
Journal: Allergy (2021)

Tyrophagus putresecentiae is an important mite species in rural and urban environments, causing sensitization and allergic disease. While evidence suggests that microRNAs (miRNAs) may regulate the expression of allergen-encoding genes, no study has directly investigated this possibility. Here, this gap was addressed by profiling miRNAs and elucidating their target allergen messenger RNAs (mRNAs) in this mite species.Small RNA and transcriptome libraries were constructed for eggs, larvae, nymphs, and adults. After deep miRNA and whole-transcriptome sequencing were performed, the miRNA and allergen-encoding mRNA regulatory networks were explored.A total of 540 miRNAs were identified, including 155 with expression levels differing significantly across the four mite developmental stages (p < .01), 59 of which were novel. The mRNA expression for allergens was higher for Tyr p 1 in adults than in other developmental stages; Tyr p 2-5, 7, 10, 13, 33, and 34 in immature stages; and Tyr p 28, 35, and 36 in eggs and adults. A combined miRNA and transcriptome bioinformatics analysis showed that allergen Tyr p 3 was regulated by miRNA PC-5p-5698441_1, Tyr p 4 was regulated by PC-5p-7050653_1, and Tyr p 34 was regulated by PC-5p-5534223_1 and PC-5p-5698441_1. These three allergen mRNA and three miRNAs were identified using qRT-PCR, and their regulatory roles were confirmed by double-fluorescent reporter gene system and site-directed mutagenesis technology.For the first time, allergen mRNA expression and miRNAs were profiled throughout the life cycle for an allergen-producing mite, and the results showed that miRNAs bind to target allergen mRNAs to regulate their expression.
1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results
Authors: D. Rischin, B.G.M. Hughes, N. Basset-Séguin, D. Schadendorf, S. Bowyer, S. Trabelsi, F. Meier, T. Eigentler, V. Casado Echarren, M.R. Migden, A. Hauschild, C.D. Schmults, S-Y. Yoo, A. Paccaly, V. Jankovic, F. Seebach, S. Drutman, J. Booth, M.G. Fury, A. Guminski
Journal: Annals of Oncology (2021)
997P STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies
Authors: G. de Castro Jr., D. Kashiura, G. Harada, L. Lima Torres, A. Codima, G. Monteiro, I.G. Costa, G.S. Julian
Journal: Annals of Oncology (2021)
Afghanistan’s health system nears collapse as donors withdraw support
Authors: Luke Taylor
Journal: BMJ (2021)

Afghanistan’s health system is collapsing and will cause an imminent humanitarian crisis if not tackled by international donors, say World Health Organization officials and medical non-governmental organisations (NGOs) responding to the country’s health emergency.

Some healthcare professionals fled the country once the Islamist fundamental group known as the Taliban took control on 15 August, and many have since stopped working because they are not being paid.

Only 17% of the 2300 health facilities run by the Sehatmandi project on which the country relies are fully functional, say WHO officials, and two thirds lack essential medicines. Nine of Afghanistan’s 37 covid hospitals have closed, and all facets of the covid …
Extracellular vesicles: The key for precision medicine in glioblastoma
Authors: Massimiliano Del Bene, Daniela Osti, Stefania Faletti, Galina V Beznoussenko, Francesco DiMeco, Giuliana Pelicci
Journal: Neuro-Oncology (2021)

Abstract Glioblastoma (GBM) represents the most aggressive and lethal disease of the central nervous system. Diagnosis is delayed following the occurrence of symptoms, and treatment is based on standardized approaches that are unable to cope with its heterogeneity, mutability, and invasiveness. The follow-up of patients relies on burdensome schedules for magnetic resonance imaging (MRI). However, to personalize treatment, biomarkers and liquid biopsy still represent unmet clinical needs. Extracellular vesicles (EVs) may be the key to revolutionize the entire process of care for patients with GBM. EVs can be collected noninvasively (eg, blood) and impressively possess multilayered information, which is constituted by their concentration and molecular cargo. EV-based liquid biopsy may facilitate GBM diagnosis and enable the implementation of personalized treatment, resulting in customized care for each patient and for each analyzed time point of the disease, thereby tackling the distinctive heterogeneity and mutability of GBM that confounds effective treatment. Herein, we discuss the limitations of current GBM treatment options and the rationale behind the need for personalized care. We also review the evidence supporting GBM-associated EVs as a promising tool capable of fulfilling the still unmet clinical need for effective and timely personalized care of patients with GBM.
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US
Authors: Lilyana Amezcua, Victor M. Rivera, Teresa Corona Vazquez, Lourdes Baezconde-Garbanati, Annette Langer-Gould
Journal: JAMA Neurology (2021)

There is empirical evidence that social determinants of health (SDOH) impact health outcomes in Black and Hispanic and Latinx individuals in the US. Recently, SDOH have risen to the top as essential intervention targets that could help alleviate racial and ethnic disparities. Neuromyelitis optica spectrum disorder (NMOSD) disproportionately affects Black individuals, and multiple sclerosis (MS) has seen a recent shift in select racial groups. It is unclear to what degree SDOH have been investigated and contribute to racial and ethnic health disparities and inequities.This narrative review provides a contemporary synthesis of SDOH associated with racial and ethnic health disparities and inequities in MS, NMOSD, and other autoimmune disorders, such as myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated disease. These immune-mediated neurological diseases were chosen for their capacity to be a high burden to society and because of complementary SDOH-associated challenges among minority populations. A paucity of research addressing inequities and the role of SDOH in MS and NMOSD was noted despite findings that Black individuals have a higher risk of developing MS or NMOSD and associated mortality compared with White individuals. Greater health disparities were also found for those with lower income and education, lower health literacy, and negative illness perceptions in MS. No studies in MOG-Ab disorders were found.Increased efforts are needed to better understand the role of SDOH in racial and ethnic health disparities and inequities in MS, NMOSD, and emerging autoimmune disorders. This includes developing research frameworks aimed at understanding the magnitude and interrelationships of SDOH to better develop system-based multilevel interventions across the spectrum of care for these neurological conditions.
Fundamentals of Human Physiology.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence of adenomatous polyposis in a fecal immunochemical test-based colorectal cancer screening program and risk of advanced neoplasia during follow-up
Authors: Sabela Carballal, Ariadna Sánchez, Leticia Moreira, Jesús Eduardo Cuellar-Monterrubio, Julio Bernuy, Maria Daca, Oswaldo Ortiz, Teresa Ocaña, Liseth Rivero-Sánchez, Gerhard Jung, Anna Serradesanferm, Angels Pozo, Jaume Grau, Isabel Torá, Diana Zaffalon, Antoni Castells, María Pellisé, Francesc Balaguer
Journal: Endoscopy (2021)

BACKGROUND : Current guidelines recommend genetic counseling and intensive colonoscopy surveillance for patients with ≥ 10 colorectal adenomas based on scarce data. We investigated the prevalence of this condition in a fecal immunochemical test (FIT)-based colorectal (CRC) screening program, and the incidence of metachronous lesions during follow-up.We retrospectively included all FIT-positive participants with ≥ 10 adenomas at index colonoscopy between 2010 and 2018. Surveillance colonoscopies were collected until 2019. Patients with inherited syndromes, serrated polyposis syndrome, total colectomy, or lacking surveillance data were excluded. The cumulative incidence of CRC and advanced neoplasia were analyzed by Kaplan-Meier analysis. Risk factors for metachronous advanced neoplasia were investigated by multivariable logistic regression analysis.215 of 9582 participants (2.2 %) had ≥ 10 adenomas. Germline genetic testing was performed in 92 % of patients with ≥ 20 adenomas, identifying two inherited syndromes (3.3 %). The 3-year cumulative incidence of CRC and advanced neoplasia were 1 % and 16 %, respectively. In 39 patients (24.2 %), no polyps were found on first surveillance colonoscopy. The presence of an advanced adenoma was independently associated with a higher risk of advanced neoplasia at first surveillance colonoscopy (odds ratio 3.91, 95 %CI 1.12-13.62; P = 0.03). Beyond the first surveillance colonoscopy, the risk of metachronous advanced neoplasia was lower.The prevalence of ≥ 10 adenomas in a FIT-based CRC screening program was 2.2 %; a small proportion of inherited syndromes were detected, even amongst those with ≥ 20 adenomas. A low rate of post-colonoscopy CRC was observed and the risk of advanced neoplasia beyond the first surveillance colonoscopy tended to progressively decrease throughout successive follow-ups.
Baseline predictors of different types of treatment success in rheumatoid arthritis
Authors: Dafne Capelusnik, Daniel Aletaha
Journal: Annals of the Rheumatic Diseases (2021)

To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures.We used data from three rheumatoid arthritis (RA) trials (one for main analysis, two for validation) to analyse the effect of patient and disease characteristics, core set measure and composite indices on the achievement of different outcomes: response outcomes (% of patients achieving a relative response margin); state outcomes (remission or low disease activity, LDA) and change outcomes (numerical change on metric scales).We included patients from the ASPIRE trial (for analysis) and from the ATTRACT and GO-BEFORE trials (for validation). While lower disease activity components at baseline-except acute phase reactants-were associated with achievement of state outcomes (such as LDA by the Simplified Disease Activity Index, SDAI), higher baseline values were associated with change outcomes (such as SDAI absolute change). A multivariate analysis of the identified predictors of state outcomes identified best prediction by a combination of shorter disease duration, male gender and lower disease activity. For prediction of response, no consistently significant predictors were found, again, with exception of C reactive protein, for which higher levels at baseline were associated with better responses.Prediction of treatment success is limited in RA. Particularly in early RA, prediction of state targets can be achieved by lower baseline levels of diseases activity. Gender and disease duration may improve the predictability of state targets. In clinical trials, included populations and choice of outcomes can be coordinated to maximise efficiency from these studies.
1530P Outcome of primary soft tissue or bone myoepithelial tumors (METs)
Authors: S. Cavaillon, M. Toulmonde, J. Wallet, Y.M. Robin, C. Honoré, F. Duffaud, P. Anract, P. Rosset, S. Carrere, C. Lebbe, E. Bompas, P. Dubray-Longeras, F. Bertucci, J. Gantzer, C.M. Chevreau, N. Mesli, J-B. Courreges, C. Chemin-Airiau, A. Dufresne, N. Penel
Journal: Annals of Oncology (2021)
Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer
Authors: Alexey A. Soshnev, C. David Allis, Ethel Cesarman, Ari M. Melnick
Journal: Cancer Research (2021)

Aberrant cell fate decisions due to transcriptional misregulation are central to malignant transformation. Histones are the major constituents of chromatin, and mutations in histone-encoding genes are increasingly recognized as drivers of oncogenic transformation. Mutations in linker histone H1 genes were recently identified as drivers of peripheral lymphoid malignancy. Loss of H1 in germinal center B cells results in widespread chromatin decompaction, redistribution of core histone modifications, and reactivation of stem cell-specific transcriptional programs. This review explores how linker histones and mutations therein regulate chromatin structure, highlighting reciprocal relationships between epigenetic circuits, and discusses the emerging role of aberrant three-dimensional chromatin architecture in malignancy.
153P Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status
Authors: S. Paluch-Shimon, H. Lueck, J. Beith, E. Tokunaga, J. Reyes Contreras, R.O. de Sant’Ana, T. Forrester, R. McNaughton, J. Wei, N. Harbeck
Journal: Annals of Oncology (2021)
Bonds and signals underlie the music learning experience
Authors: Steven J Morrison
Journal: Behavioral and Brain Sciences (2021)

The music learning environment is a context in which fundamental forces and values underlying human musicality may be evident. Social bonding within music-making groups is characterized by a high degree of complexity whereas issues of clarity, accuracy, and coordination remain the focus of learning. Physical and cognitive impairments that compromise music learning opportunities offer a critical test of music's link to social bonding.
Diosgenin inhibits growth and induces apoptosis in HCT-116 human colon adenocarcinoma cells by modulating the cholesterol biosynthetic pathway
Authors: Jayadev Raju, Kevin De Carteret, Ranjana Bird
Journal: Cancer Research (2006)

3919  Diosgenin, a steroid saponin, is abundantly found in wild yams (Dioscorea villosa Linn) and seeds of fenugreek (Trigonella foenum graecum Linn) and has gained importance as a prospective cancer preventive agent. In this study, we investigated if growth inhibition of HCT-116 human colon adenocarcinoma cells by diosgenin involves the induction of apoptosis. Furthermore, we evaluated if the molecular mechanism of diosgenin involves modulation of key molecules of the cholesterol biosynthetic pathway. Diosgenin treatment resulted in a dose-dependent decrease in the viability and growth of HCT-116 cells. The LD50 of diosgenin in HCT-116 was ∼20 μM after 24 h, and decreased to 7-10 μM after 48 and 72 h treatments. Diosgenin induced apoptosis dose-dependently and involved cleavage of poly (ADP-ribose) polymerase (PARP). The expression of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase was significantly lowered by increasing concentrations of diosgenin. This was accompanied by a dose-dependent decrease in low-density lipoprotein (LDL) receptor. Furthermore, diosgenin treatment resulted in a significant, dose-dependent decrease in the expressions of β-catenin, peroxisome proliferator-activated receptor (PPAR) -γ, insulin-like growth factor (IGF)-1 and IGF-1 receptor in HCT-116 cells. Our data suggests that diosgenin is a potent inhibitor of HCT-116 colon adenocarcinoma cells by inducing apoptosis and inhibiting multiple molecular targets including the cholesterol biosynthetic pathway, and the Wnt and IGF-1-mediated pathways. In conclusion, our results indicate the molecular mode of action of diosgenin and its potential use as a chemopreventive agent against colon cancer.
Appropriateness of Opioid Prescription in Children, Adolescents, and Younger Adults—The Elephant in the Room—Reply
Authors: Madeline H. Renny, Scott E. Hadland, Magdalena Cerdá
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Substance P stimulates human airway submucosal gland secretion mainly via a CFTR-dependent process
Authors: Jae Young Choi, Monal Khansaheb, Nam Soo Joo, Mauri E. Krouse, Robert C. Robbins, David Weill, Jeffrey J. Wine
Journal: Journal of Clinical Investigation (2010)

Chronic bacterial airway infections are the major cause of mortality in cystic fibrosis (CF). Normal airway defenses include reflex stimulation of submucosal gland mucus secretion by sensory neurons that release substance P (SubP). CFTR is an anion channel involved in fluid secretion and mutated in CF; the role of CFTR in secretions stimulated by SubP is unknown. We used optical methods to measure SubP-mediated secretion from human submucosal glands in lung transplant tissue. Glands from control but not CF subjects responded to mucosal chili oil. Similarly, serosal SubP stimulated secretion in more than 60% of control glands but only 4% of CF glands. Secretion triggered by SubP was synergistic with vasoactive intestinal peptide and/or forskolin but not with carbachol; synergy was absent in CF glands. Pig glands demonstrated a nearly 10-fold greater response to SubP. In 10 of 11 control glands isolated by fine dissection, SubP caused cell volume loss, lumen expansion, and mucus flow, but in 3 of 4 CF glands, it induced lumen narrowing. Thus, in CF, the reduced ability of mucosal irritants to stimulate airway gland secretion via SubP may be another factor that predisposes the airways to infections.
1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Authors: I. Pires da Silva, D. Zakria, T. Ahmed, C. Trojaniello, F. Dimitriou, C. Allayous, C. Gerard, L. Zimmer, S. Lo, O.A. Michielin, C. Lebbe, J. Mangana, P.A. Ascierto, D. Johnson, M. Carlino, A.M. Menzies, G.V. Long
Journal: Annals of Oncology (2021)
以前に治療した選択された固形腫瘍患者におけるレンバチニブ+ペンブロリズマブのP-139A相2マルチコホート研究(LEAP-005):膵臓癌コホート【JST・京大機械翻訳】|||
Authors: H Chung, L Villanueva, D Graham, E Saada-Bouzid, R Ghori, P Kubiak, B Gumuscu, N Lerman, C Gomez-Roca
Journal: Annals of Oncology (2021)
Movement control, decision-making, and the building of Roman roads to link them
Authors: Reza Shadmehr, Alaa A. Ahmed
Journal: Behavioral and Brain Sciences (2021)

Abstract In science, as in life, one can only hope to both inform others, and be informed by them. The commentaries associated with our book Vigor have highlighted the many ways in which the theory that we proposed can be improved. For example, there are a myriad of factors that need to be considered in a fully encompassing objective function. The neural mechanisms underlying the links between movement and decision-making have yet to be unraveled. The implications of a two-way interaction between movement and decisions at both the individual and social levels remain to be understood. The commentaries outline future questions, and encouragingly highlight the diversity of science communities that may be linked via the concept of vigor.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Authors: Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W Flaig, Fabio Franke, Oscar B Goodman, Stéphane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman-May, Susan Li, Jinhui Li, Shibu Thomas, Katherine B Bevans, Suneel D Mundle, Sharon A McCarthy, Dana E Rathkopf
Journal: The Lancet Oncology (2021)
1820P Hybrid circulating tumor cells in breast cancer
Authors: S. Vtorushin, O.E. Savelieva, L.A. Tashireva, T.S. Gerashchenko, R. Mukhamedzhanov, N.A. Tarabanovskaya, E.S. Grigoryeva, M.V. Zavyalova, V.M. Perelmuter
Journal: Annals of Oncology (2021)